Search research articles
Contact Us
Filters
Showing results (181-190 of 471) with videos related to
Page
of 48
Sort By:
American Heart Journal
|
January 29, 2013
Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial
Andrew P Ambrosy, Muthiah Vaduganathan, Robert J Mentz, et al.
European Journal of Heart Failure
|
June 22, 2013
Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial
Nicolas Girerd, Peter S Pang, Karl Swedberg, et al.
Circulation
|
June 29, 2005
Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure
Salim Yusuf, Jan B Ostergren, Hertzel C Gerstein, et al.
Journal of the American College of Cardiology
|
August 13, 2013
Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients
Jan-Christian Reil, Jean-Claude Tardif, Ian Ford, et al.
The American Journal of Cardiology
|
September 25, 2012
Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial)
Ami N Shah, Robert J Mentz, Mihai Gheorghiade, et al.
The American Journal of Cardiology
|
August 25, 2012
Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial)
Stephen J Greene, Matthew E Harinstein, Muthiah Vaduganathan, et al.
BMC Geriatrics
|
March 27, 2023
Integrating health promotion with and for older people - eHealth (IHOPe) - evaluating remote integrated person-centred care : Protocol of a randomised controlled trial with effectiveness, health economic, and process evaluation
Zahra Ebrahimi, Emmelie Barenfeld, Hanna Gyllensten, et al.
Journal of the American College of Cardiology
|
May 16, 2006
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program
Lars G Olsson, Karl Swedberg, Anique Ducharme, et al.
European Heart Journal
|
March 29, 2013
Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials
Kim Fox, Michel Komajda, Ian Ford, et al.
Lancet (London, England)
|
December 13, 2005
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial
Bradi B Granger, Karl Swedberg, Inger Ekman, et al.
Page
of 48
Search research articles
Search
Showing results (181-190 of 471) with videos related to
Sort By:
Page
of 48
American Heart Journal
|
January 29, 2013
Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial
Andrew P Ambrosy, Muthiah Vaduganathan, Robert J Mentz, et al.
European Journal of Heart Failure
|
June 22, 2013
Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial
Nicolas Girerd, Peter S Pang, Karl Swedberg, et al.
Circulation
|
June 29, 2005
Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure
Salim Yusuf, Jan B Ostergren, Hertzel C Gerstein, et al.
Journal of the American College of Cardiology
|
August 13, 2013
Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients
Jan-Christian Reil, Jean-Claude Tardif, Ian Ford, et al.
The American Journal of Cardiology
|
September 25, 2012
Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial)
Ami N Shah, Robert J Mentz, Mihai Gheorghiade, et al.
The American Journal of Cardiology
|
August 25, 2012
Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial)
Stephen J Greene, Matthew E Harinstein, Muthiah Vaduganathan, et al.
BMC Geriatrics
|
March 27, 2023
Integrating health promotion with and for older people - eHealth (IHOPe) - evaluating remote integrated person-centred care : Protocol of a randomised controlled trial with effectiveness, health economic, and process evaluation
Zahra Ebrahimi, Emmelie Barenfeld, Hanna Gyllensten, et al.
Journal of the American College of Cardiology
|
May 16, 2006
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program
Lars G Olsson, Karl Swedberg, Anique Ducharme, et al.
European Heart Journal
|
March 29, 2013
Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials
Kim Fox, Michel Komajda, Ian Ford, et al.
Lancet (London, England)
|
December 13, 2005
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial
Bradi B Granger, Karl Swedberg, Inger Ekman, et al.
Page
of 48